HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Texereau, J Articles by Dinh-Xuan, A T Search for Related Content PubMed PubMed Citation Articles by Texereau, J Articles by Dinh-Xuan, A T

Nitric oxide synthase 1 as a potential modifier gene of decline in lung function in patients with cystic fibrosis

¹ Service de Physiologie-Explorations Fonctionnelles, Hôpital Cochin, AP-HP, Université Paris 5, Paris, France
² Department of Cell Biology, Institut Cochin, INSERM, CNRS, Paris, France
³ Service de Pneumologie, Hôpital Cochin, AP-HP, Université Paris 5, Paris, France
⁴ Service d’Informatique Médicale et de Biostatistiques, Hôpital Cochin, AP-HP, Université Paris 5, Paris, France

Correspondence to:
Correspondence to:
Professor A T Dinh-Xuan
Service de Physiologie-Explorations Fonctionnelles, Hôpital Cochin, 27 rue du faubourg Saint-Jacques, 75014 Paris, France; anh-tuan.dinh-xuan{at}cch.ap-hop-paris.fr

ABSTRACT
Background: The severity of lung disease varies widely in patients with cystic fibrosis (CF) who have the same type of mutations of the cystic fibrosis transmembrane regulator (CFTR) gene, suggesting involvement of "modifier" genes. The nitric oxide synthase 1 (NOS1) gene is a candidate for this role because exhaled nitric oxide (NO) is reduced in patients with CF and NOS1 activity contributes to transepithelial ionic transport, immune defence, and non-specific inflammation of the airways.

Methods: Dinucleotide GT repeat polymorphism was studied in the 5' untranslated region of the NOS1 gene, immediately upstream from the transcription initiation site, in 59 patients with CF and 59 healthy controls.

Results: Nineteen alleles of the NOS1 gene were identified according to the number of GT repeats (from 18 to 36) in the 5 untranslated region. Exhaled NO levels were significantly correlated with the number of GT repeats. Patients with CF who had the NOS1 genotype associated with high NO production had a slower decline in lung function during the 5 year follow up period. There was no confounding effect of age, chronic bacterial colonisation of the airway, or CFTR genotype.

Conclusions: These data suggest a possible link between the NOS1 gene locus and the rate of decline in lung function in patients with CF.

Keywords: polymorphism; nitric oxide synthase 1 (NOS1) gene; genetics; cystic fibrosis; lung function

This article has been cited by other articles:

				C. Grasemann, F. Ratjen, D. Schnabel, E. Reutershahn, U. Vester, and H. Grasemann Effect of growth hormone therapy on nitric oxide formation in cystic fibrosis patients Eur. Respir. J., April 1, 2008; 31(4): 815 - 821. [Abstract] [Full Text] [PDF]

				I. Aznarez, J. Zielenski, J. M Rommens, B. J Blencowe, and L.-C. Tsui Exon skipping through the creation of a putative exonic splicing silencer as a consequence of the cystic fibrosis mutation R553X J. Med. Genet., May 1, 2007; 44(5): 341 - 346. [Abstract] [Full Text] [PDF]

				J. Laki, I. Laki, K. Nemeth, R. Ujhelyi, O. Bede, E. Endreffy, K. Bolbas, K. Gyurkovits, E. Csiszer, E. Solyom, et al. The 8.1 ancestral MHC haplotype is associated with delayed onset of colonization in cystic fibrosis Int. Immunol., November 1, 2006; 18(11): 1585 - 1590. [Abstract] [Full Text] [PDF]

				H. Grasemann, F. Kurtz, and F. Ratjen Inhaled L-Arginine Improves Exhaled Nitric Oxide and Pulmonary Function in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., July 15, 2006; 174(2): 208 - 212. [Abstract] [Full Text] [PDF]

				P. J. Franklin, G. L. Hall, A. Moeller, F. Horak, S. Brennan, and S. M. Stick Exhaled nitric oxide is not reduced in infants with cystic fibrosis Eur. Respir. J., February 1, 2006; 27(2): 350 - 354. [Abstract] [Full Text] [PDF]

				H. Grasemann, C. Grasemann, F. Kurtz, G. Tietze-Schillings, U. Vester, and F. Ratjen Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study Eur. Respir. J., January 1, 2005; 25(1): 62 - 68. [Abstract] [Full Text] [PDF]

				Lucina Arch. Dis. Child., August 1, 2004; 89(8): 798 - 798. [Full Text] [PDF]

				Nitric oxide synthase 1 and prognosis in cystic fibrosis J. Clin. Pathol., April 1, 2004; 57(4): 434 - 434. [Full Text]